Get the Stockscreener App
7.64
0.65%
-0.05
After Hours:
7.65
0.01
+0.13%
Imagenebio Inc stock is traded at $7.64, with a volume of 14,314.
It is down -0.65% in the last 24 hours and down -16.41% over the past month.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
See More
Previous Close:
$7.69
Open:
$7.61
24h Volume:
14,314
Relative Volume:
0.32
Market Cap:
$85.99M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.39%
1M Performance:
-16.41%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.56
$7.78
1-Week Range:
$7.47
$8.545
52-Week Range:
$7.47
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Name
Imagenebio Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
7.64 | 85.99M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Imagenebio Inc Stock (IMA) Latest News
OX40 Targeted Therapy Clinical Trials Anti OX40 Antibody Development Market Opportunity Insight 2026 - GlobeNewswire Inc.
ImageneBio CFO Jotin Marango resigns, company to begin search for successor - Investing.com Australia
ImageneBio CFO Resignation Announced - TipRanks
ImageneBio (NASDAQ:IMA) Cut to “Hold” at Zacks Research - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold - Defense World
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - msn.com
ImageneBio (NASDAQ:IMA) Stock Price Down 1.2% – Here’s Why - Defense World
ImageneBio files to sell 2.51M shares of common stock for holders - MSN
ImageneBio (NASDAQ:IMA) Shares Down 1.3%Should You Sell? - MarketBeat
ImageneBio (NASDAQ:IMA) Shares Down 1.3% – Should You Sell? - Defense World
HUTCHMED Reports 2025 Interim Results - GlobeNewswire
Ikena Oncology (IMA) Projected to Post Quarterly Earnings on Thursday - Defense World
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
Q3 EPS Estimates for Ikena Oncology Lifted by William Blair - Defense World
William Blair Comments on Ikena Oncology FY2029 Earnings - Defense World
ImageneBio Approves 2025 Inducement Plan for Employees - The Globe and Mail
ImageneBio board approves 2025 inducement plan for new employee equity awards - Investing.com Australia
ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent - AInvest
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ImageneBio Grants Massive $9.6M Equity Package: New CEO Gets 436K Stock Options, 153K RSUs - Stock Titan
Imagenebio shares rise 7.26% premarket after insider bought shares worth $7.999.924. - AInvest
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025 - AInvest
Ikena Oncology Completes Merger, Becomes ImageneBio, Inc. - The Globe and Mail
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) - MarketScreener
IMA Stock Price and Chart — NASDAQ:IMA - TradingView
ImageneBio Appoints Kristin Yarema as CEO, Merges with Ikena Oncology, Raises $75M - AInvest
ImageneBio Launches on Nasdaq Following Merger, Raises $75M for Skin Treatment Development - CTOL Digital Solutions
Ikena Oncology shares fall 2.03% after-hours following acquisition by Inmagene Biopharmaceuticals. - AInvest
Inmagene Biopharmaceuticals Announces Completion of Merger - GlobeNewswire
Ikena Oncology Completes Merger with Inmagene Biopharmaceuticals - TipRanks
ImageneBio's Strategic Rebirth: A Catalyst for Long-Term Shareholder Value in the Atopic Dermatitis Market - AInvest
Inmagene-Ikena $75M Merger Creates New Atopic Dermatitis Drug Powerhouse ImageneBio - Stock Titan
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio - Investing.com
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company By Investing.com - Investing.com South Africa
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company - Investing.com Nigeria
iKena Oncology appoints Yarema as CEO of ImageneBio - TipRanks
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm - Investing.com
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology Stockholders Approve Merger With Inmagene Biopharmaceuticals - citybiz
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com India
Ikena Oncology Announces 1-for-12 Reverse Stock Split and Merger with Inmagene Biopharmaceuticals, to Trade as ImageneBio, Inc. on Nasdaq Under Ticker “IMA” | IKNA Stock News - Quiver Quantitative
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com
Ikena Oncology Announces ISS and Glass Lewis Recommend - GlobeNewswire
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial - GlobeNewswire
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - MarketScreener
Inmagene Reports Topline Results from Phase 2a Study of - GlobeNewswire
Imagenebio Inc Stock (IMA) Financials Data
There is no financial data for Imagenebio Inc (IMA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):